{"title":"[Expert consensus on subcutaneous cluster immunotherapy of inhaled allergens].","authors":"","doi":"10.3760/cma.j.cn112150-20240928-00781","DOIUrl":null,"url":null,"abstract":"<p><p>Allergen-specific immunotherapy is the only etiological treatment that can prevent the progression of allergic diseases at present. Cluster immunotherapy is an improved immunotherapy regimen, which shortens the dose escalation period from 4-6 months in conventional regimen to 1-8 weeks. In the past, there was no consensus or guideline to guide the standardized application of subcutaneous cluster immunotherapy of inhaled allergens in China. Based on relevant research evidence at home and abroad and the opinions of industry experts, this consensus systematically expounded the indications and contraindications of cluster immunotherapy, and proposed that the cluster scheme took effect earlier than the conventional scheme, with similar incidence of systemic allergic reaction with the conventional scheme. At the same time, the risk factors and preventive measures of systemic allergic reaction caused by cluster immunotherapy were emphasized. This consensus aims to improve the understanding of cluster immunotherapy among medical staff in China and guide the standardized application and management of cluster immunotherapy.</p>","PeriodicalId":24033,"journal":{"name":"中华预防医学杂志","volume":"58 12","pages":"1825-1834"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华预防医学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112150-20240928-00781","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Allergen-specific immunotherapy is the only etiological treatment that can prevent the progression of allergic diseases at present. Cluster immunotherapy is an improved immunotherapy regimen, which shortens the dose escalation period from 4-6 months in conventional regimen to 1-8 weeks. In the past, there was no consensus or guideline to guide the standardized application of subcutaneous cluster immunotherapy of inhaled allergens in China. Based on relevant research evidence at home and abroad and the opinions of industry experts, this consensus systematically expounded the indications and contraindications of cluster immunotherapy, and proposed that the cluster scheme took effect earlier than the conventional scheme, with similar incidence of systemic allergic reaction with the conventional scheme. At the same time, the risk factors and preventive measures of systemic allergic reaction caused by cluster immunotherapy were emphasized. This consensus aims to improve the understanding of cluster immunotherapy among medical staff in China and guide the standardized application and management of cluster immunotherapy.
期刊介绍：
Chinese Journal of Preventive Medicine (CJPM), the successor to Chinese Health Journal , was initiated on October 1, 1953. In 1960, it was amalgamated with the Chinese Medical Journal and the Journal of Medical History and Health Care , and thereafter, was renamed as People’s Care . On November 25, 1978, the publication was denominated as Chinese Journal of Preventive Medicine . The contents of CJPM deal with a wide range of disciplines and technologies including epidemiology, environmental health, nutrition and food hygiene, occupational health, hygiene for children and adolescents, radiological health, toxicology, biostatistics, social medicine, pathogenic and epidemiological research in malignant tumor, surveillance and immunization.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
